Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

A new generative AI model rapidly generates diverse antimicrobial peptide structures for screening against ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for ...

Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1b Inhalation Solution, a self-developed product by ...

Encoded’s layoffs will mostly affect its technology and early-stage research and development functions. The move is expected ...

Can-Fite’s lead drug candidate, Piclidenoson ... who will share insight into the Company’s current development pipeline and upcoming milestones. Strategically positioned with multiple out ...